Y-mAbs Therapeutics Inc (YMAB)
11.56
-0.29
(-2.45%)
USD |
NASDAQ |
May 17, 16:00
11.56
0.00 (0.00%)
After-Hours: 20:00
Y-mAbs Therapeutics Enterprise Value: 433.29M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 433.29M |
| May 16, 2024 | 444.26M |
| May 15, 2024 | 458.74M |
| May 14, 2024 | 442.94M |
| May 13, 2024 | 459.18M |
| May 10, 2024 | 463.13M |
| May 09, 2024 | 489.02M |
| May 08, 2024 | 521.49M |
| May 07, 2024 | 679.47M |
| May 06, 2024 | 680.79M |
| May 03, 2024 | 676.84M |
| May 02, 2024 | 681.23M |
| May 01, 2024 | 647.88M |
| April 30, 2024 | 591.71M |
| April 29, 2024 | 604.28M |
| April 26, 2024 | 569.62M |
| April 25, 2024 | 575.32M |
| April 24, 2024 | 595.06M |
| April 23, 2024 | 597.26M |
| April 22, 2024 | 589.36M |
| April 19, 2024 | 588.04M |
| April 18, 2024 | 582.04M |
| April 17, 2024 | 586.86M |
| April 16, 2024 | 588.18M |
| April 15, 2024 | 578.09M |
| Date | Value |
|---|---|
| April 12, 2024 | 554.41M |
| April 11, 2024 | 565.81M |
| April 10, 2024 | 528.98M |
| April 09, 2024 | 541.26M |
| April 08, 2024 | 557.92M |
| April 05, 2024 | 558.36M |
| April 04, 2024 | 562.74M |
| April 03, 2024 | 556.61M |
| April 02, 2024 | 571.52M |
| April 01, 2024 | 634.22M |
| March 31, 2024 | 637.29M |
| March 28, 2024 | 633.18M |
| March 27, 2024 | 643.69M |
| March 26, 2024 | 608.66M |
| March 25, 2024 | 609.10M |
| March 22, 2024 | 631.87M |
| March 21, 2024 | 662.95M |
| March 20, 2024 | 599.47M |
| March 19, 2024 | 573.20M |
| March 18, 2024 | 523.74M |
| March 15, 2024 | 564.89M |
| March 14, 2024 | 578.02M |
| March 13, 2024 | 614.79M |
| March 12, 2024 | 625.74M |
| March 11, 2024 | 643.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
16.48M
Minimum
Nov 03 2022
2.067B
Maximum
Dec 17 2020
749.08M
Average
637.11M
Median
Aug 03 2022
Enterprise Value Benchmarks
| The Cooper Companies Inc | 21.97B |
| Puma Biotechnology Inc | 190.40M |
| Humacyte Inc | 638.30M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.629M |
| Revenue (Quarterly) | 19.93M |
| Total Expenses (Quarterly) | 26.84M |
| EPS Diluted (Quarterly) | -0.15 |
| Gross Profit Margin (Quarterly) | 89.23% |
| Profit Margin (Quarterly) | -33.26% |
| Earnings Yield | -4.22% |
| Normalized Earnings Yield | -4.224 |